All In Biotech

Drug Trial Radar · NCT03149640

Study Comparing Inhaled Amikacin Versus Placebo to Prevent Ventilator Associated Pneumonia

Double-blinded Multicenter Randomized Controlled Trial Comparing Inhaled Amikacin Versus Placebo to Prevent Ventilator Associated Pneumonia

Last checked: Nov 19, 2026Latest source record: Dec 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 850 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

850

Actual

Start

Jul 19, 2017

Primary completion

Mar 9, 2021

Study completion Jun 17, 2021

Sponsor

Lead sponsor
University Hospital, ToursAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 11, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of the study is to prove that after the third day of invasive mechanical ventilation a three-day course of inhaled amikacin reduces the incidence of subsequent VAP. Parallel two group double blind randomized controlled clinical trial. Individual randomization, performed on day 4 of invasive mechanical ventilation, will be stratified on centre in order to account for variations in VAP prevention bundle implementation and use of systemic antibiotics the day of randomization. Patients will be treated three consecutive days with inhaled amikacin or placebo. Patients will be followed up daily in the intensive care unit for the occurrence of VAP according to international guidelines until day 28.

Conditions

  • Pneumonia, Ventilator-Associated

Interventions

  • Inhaled amikacinDrug

    Once a day, inhaled amikacin at day 4, day 5 and day 6 of invasive mechanical ventilation: 20 mg/kg of ideal body weight, maximum 2 g per day.

  • Inhaled placeboDrug

    Once a day, inhaled placebo at day 4, day 5 and day 6 of invasive mechanical ventilation.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of a first VAP episode from randomization to day 28Time frame: Patients will be followed from randomization to day 28

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • Service de Réanimation Chirurgicale

    Angers, France

  • Service de Réanimation Médicale - CH d'Angoulême

    Angoulême, France

  • Service de Réanimation Polyvalente

    Argenteuil, France

  • Service de Réanimation Médicale - Hôpital Louis Mourier

    Colombes, France

  • Service de Réanimation

    Dijon, France

  • Service de Réanimation Médicale - CHD Les Oudairies

    La Roche-sur-Yon, France

  • Service de Réanimation

    Le Mans, France

  • Service de Réanimation Médicale - Hôpital La Croix-Rousse

    Lyon, France

  • Service de Réanimation Médicale

    Orléans, France

  • Service de Réanimation Médicale - Hôpital Pitié Salpêtrière

    Paris, France

  • Service de Réanimation Médicale - CHU La Milétrie

    Poitiers, France

  • Service de Réanimation Médicale

    Poitiers, France

  • Service de Réanimation Médicale - CHU Pontchaillou

    Rennes, France

  • Service de Réanimation Médicale - CHU Rouen

    Rouen, France

  • Service de Réanimation Médicale - Hôpital Charles Nicolle

    Rouen, France

  • Service de Réanimation - NHC

    Strasbourg, France

  • Service de Réanimation Médicale - Hôpital de Hautepierre

    Strasbourg, France

  • Service de Réanimation médicale, Hôpital Trousseau

    Tours, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.